128 related articles for article (PubMed ID: 28010996)
1. Pharmacological characterization of rat VD-hemopressin(α), an α-hemoglobin-derived peptide exhibiting cannabinoid agonist-like effects in mice.
Zheng T; Zhang T; Zhang R; Wang ZL; Han ZL; Li N; Li XH; Zhang MN; Xu B; Yang XL; Fang Q; Wang R
Neuropeptides; 2017 Jun; 63():83-90. PubMed ID: 28010996
[TBL] [Abstract][Full Text] [Related]
2. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide.
Han ZL; Fang Q; Wang ZL; Li XH; Li N; Chang XM; Pan JX; Tang HZ; Wang R
J Pharmacol Exp Ther; 2014 Feb; 348(2):316-23. PubMed ID: 24307201
[TBL] [Abstract][Full Text] [Related]
3. VF-13, a chimeric peptide of VD-hemopressin(α) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects.
Xu B; Xiao J; Xu K; Zhang Q; Chen D; Zhang R; Zhang M; Zhu H; Niu J; Zheng T; Li N; Zhang X; Fang Q
Neuropharmacology; 2020 Sep; 175():108178. PubMed ID: 32544481
[TBL] [Abstract][Full Text] [Related]
4. CB
Zheng T; Zhang R; Zhang T; Zhang MN; Xu B; Song JJ; Li N; Tang HH; Wang P; Wang R; Fang Q
Brain Res; 2018 Feb; 1680():155-164. PubMed ID: 29274880
[TBL] [Abstract][Full Text] [Related]
5. Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice.
Li XH; Lin ML; Wang ZL; Wang P; Tang HH; Lin YY; Li N; Fang Q; Wang R
Neurogastroenterol Motil; 2016 Jun; 28(6):891-9. PubMed ID: 26991932
[TBL] [Abstract][Full Text] [Related]
6. Effects of neuropeptide FF and related peptides on the antinociceptive activities of VD-hemopressin(α) in naive and cannabinoid-tolerant mice.
Pan JX; Wang ZL; Li N; Zhang N; Wang P; Tang HH; Zhang T; Yu HP; Zhang R; Zheng T; Fang Q; Wang R
Eur J Pharmacol; 2015 Nov; 767():119-25. PubMed ID: 26472125
[TBL] [Abstract][Full Text] [Related]
7. Analgesic tolerance and cross-tolerance to the cannabinoid receptors ligands hemopressin, VD-hemopressin(α) and WIN55,212-2 at the supraspinal level in mice.
Pan JX; Wang ZL; Li N; Han ZL; Li XH; Tang HH; Wang P; Zheng T; Fang Q; Wang R
Neurosci Lett; 2014 Aug; 578():187-91. PubMed ID: 25010019
[TBL] [Abstract][Full Text] [Related]
8. Antinociceptive effects of the endogenous cannabinoid peptide agonist VD-hemopressin(β) in mice.
Wang P; Zheng T; Zhang M; Xu B; Zhang R; Zhang T; Zhao W; Shi X; Zhang Q; Fang Q
Brain Res Bull; 2018 May; 139():48-55. PubMed ID: 29425797
[TBL] [Abstract][Full Text] [Related]
9. Effects of the cannabinoid 1 receptor peptide ligands hemopressin, (m)RVD-hemopressin(α) and (m)VD-hemopressin(α) on memory in novel object and object location recognition tasks in normal young and Aβ1-42-treated mice.
Zhang RS; He Z; Jin WD; Wang R
Neurobiol Learn Mem; 2016 Oct; 134 Pt B():264-74. PubMed ID: 27481221
[TBL] [Abstract][Full Text] [Related]
10. An α-hemoglobin-derived peptide (m)VD-hemopressin (α) promotes NREM sleep via the CB
Xie JF; Wang LX; Ren WT; Wang C; Gao JX; Chen HL; Zhao XQ; Ren YL; Xie YP; Shao YF; Hou YP
Front Pharmacol; 2023; 14():1213215. PubMed ID: 37456761
[TBL] [Abstract][Full Text] [Related]
11. The hypotensive effect of intrathecally injected (m)VD-hemopressin(α) in urethane-anesthetized rats.
Li XH; Li N; Wang ZL; Pan JX; Han ZL; Chang XM; Tang HH; Wang P; Wang R; Fang Q
Peptides; 2014 Jun; 56():45-51. PubMed ID: 24681436
[TBL] [Abstract][Full Text] [Related]
12. OCP002, a Mixed Agonist of Opioid and Cannabinoid Receptors, Produces Potent Antinociception With Minimized Side Effects.
Xu B; Zhang Q; Chen D; Zhang M; Zhang R; Zhao W; Qiu Y; Xu K; Xiao J; Niu J; Shi Y; Li N; Fang Q
Anesth Analg; 2023 Feb; 136(2):373-386. PubMed ID: 36638515
[TBL] [Abstract][Full Text] [Related]
13. Signaling molecules targeting cannabinoid receptors: Hemopressin and related peptides.
Wei F; Zhao L; Jing Y
Neuropeptides; 2020 Feb; 79():101998. PubMed ID: 31831183
[TBL] [Abstract][Full Text] [Related]
14. Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation.
Zhang T; Han Z; Shi X; Zhao W; Wang Z; Zhang R; Xu B; Zhang M; Zhang Q; Xiao J; Zhu H; Zheng T; Fang Q
Bioorg Med Chem; 2019 Feb; 27(4):630-643. PubMed ID: 30626554
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of EN-9, a novel chimeric peptide of endomorphin-2 and neuropeptide FF that produces potent antinociceptive activity and limited tolerance.
Wang ZL; Li N; Wang P; Tang HH; Han ZL; Song JJ; Li XH; Yu HP; Zhang T; Zhang R; Xu B; Zhang MN; Fang Q; Wang R
Neuropharmacology; 2016 Sep; 108():364-72. PubMed ID: 26970017
[TBL] [Abstract][Full Text] [Related]
16. Novel endogenous peptide agonists of cannabinoid receptors.
Gomes I; Grushko JS; Golebiewska U; Hoogendoorn S; Gupta A; Heimann AS; Ferro ES; Scarlata S; Fricker LD; Devi LA
FASEB J; 2009 Sep; 23(9):3020-9. PubMed ID: 19380512
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of morphine antinociceptive tolerance by cannabinoid CB1 and CB2 receptor antagonists.
Altun A; Yildirim K; Ozdemir E; Bagcivan I; Gursoy S; Durmus N
J Physiol Sci; 2015 Sep; 65(5):407-15. PubMed ID: 25894754
[TBL] [Abstract][Full Text] [Related]
18. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system.
Romero TR; Resende LC; Guzzo LS; Duarte ID
Anesth Analg; 2013 Feb; 116(2):463-72. PubMed ID: 23302980
[TBL] [Abstract][Full Text] [Related]
19. Effects of neuropeptide FF system on CB₁ and CB₂ receptors mediated antinociception in mice.
Fang Q; Han ZL; Li N; Wang ZL; He N; Wang R
Neuropharmacology; 2012 Feb; 62(2):855-64. PubMed ID: 21945715
[TBL] [Abstract][Full Text] [Related]
20. Systemic administration of the bifunctional opioid/neuropeptide FF receptors agonist BN-9 produced peripheral antinociception in preclinical mouse models of pain.
Li N; Han ZL; Xu B; Zhang MN; Zhang T; Shi XR; Zhao WD; Guo YY; Zhang QQ; Fang Q
Eur J Pharmacol; 2018 Oct; 837():53-63. PubMed ID: 30172787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
